Disclosure of 2026 Q1 Compliance Program Results and Q2 Plan


  • Q1 2026 CP operating results: All employees signed compliance pledges, ISO 37001 operated, 1,496 monitoring cases, CP committee and subcommittee meetings held, education and culture dissemination activities conducted, no CP sanctions
  • Q2 2026 CP operating plan: CEO declaration of compliance commitment, CP enhancement ceremony, ISO 37001 internal and external audit preparation, strengthened education, continued monitoring

KOSPI Filing Information


  • Filing: Status Of Fair Trade Compliance Program Operation (Guidance Disclosure)
  • Company: Dongwha Pharm (000020)
  • Submission: Dongwha Pharm Co., Ltd.
  • Receipt: 04-29-2026
  • Under KRX KOSPI Market Division